baseline phosphate was associated with older age, female gender, parenteral nutrition, vasopressor support, low calcium, and high urea, bilirubin and creatinine, whereas hypophosphatemia during dialysis correlated with the ischemic acute tubular necrosis etiology of renal failure, intensive dose and longer therapy. Serum phosphate decline during dialysis was associated with higher incidence of prolonged respiratory failure requiring tracheostomy [odds ratio (OR) ¼ 1.81; 95% confidence interval (CI) ¼
Introduction
Phosphate is important in normal physiology. It is the source of high-energy phosphate bonds of adenosine triphosphate, a buffer of acid-base balance in plasma and an integral component of phospholipids, nucleic acids and proteins. Hypophosphatemia has been shown to cause diaphragmatic muscular weakness and failure of weaning from ventilators [1] [2] [3] ; other complications include rhabdomyolysis, hemolytic anemia and reduced cardiac contractility [4] [5] [6] . Hypophosphatemia occurs in 2-5% of hospitalized patients and is dependent on their presenting nutritional state, nature of their acute disease and severity of illness [3, [7] [8] [9] [10] . The high incidence reported in critically ill patients is attributed to sepsis, the refeeding syndrome and diuretic use [5, 6, 8, [11] [12] [13] . Renal excretion, which plays an important role in phosphate homeostasis, is enhanced with metabolic or respiratory alkalosis and in trauma patients [9, 14, 15] . On the other hand, patients who have acute or chronic kidney disease usually develop hyperphosphatemia [16] . Dialysis, particularly in its continuous form, clears phosphate efficiently [17] [18] [19] , and hypophosphatemia often ensues, particularly with intensive treatment [20, 21] . In two recent large multi-center clinical trials, the group receiving more intense dialysis experienced a higher incidence of hypophosphatemia [20, 21] . We examine the incidence of hypophosphatemia and its association with respiratory failure requiring prolonged ventilation and all-cause mortality in critically ill patients with acute kidney injury (AKI) supported with continuous veno-venous hemodialysis (CVVHD).
Materials and methods
The Cleveland Clinic Foundation-Acute renal failure Support Registry (1995-2001) was used to identify 405 patients initially supported with bicarbonate continuous hemodialysis-353 patients had at least one serum phosphate measured while on CVVHD (Figure 1 ). The registry is a prospective observational cohort database that captures demographics, dialysis therapy and laboratory and outcome data. All supported AKI patients were recorded from 1995 to 1998 and then one in five patients from 1999 to 2001. A description of AKI registry data elements, data collection and management strategies were previously described [16, 22, 23] . Briefly, this dataset only captured patients initially started on CVVHD using heparin anticoagulation where possible. This study was approved by the Cleveland Clinic Institutional Review Board.
The primary study end points were the incidence of prolonged respiratory failure and all-cause 28-day mortality from the start of CVVHD. Prolonged respiratory failure was defined as the need for tracheostomy, excluding head and neck cancer and trauma patients. Patients with tracheotomy at initiation or requiring CVVHD for 2 days were excluded. Approximately 83% of patients had at least two serum phosphate measurements while on CVVHD-daily serum phosphate measurements were available for 67% (2046/3057) of patient-days on CVVHD (Figure 1 ). Incident hypophosphatemia (IHP) was defined as descent of serum phosphate <2 mg/dL during continuous hemodialysis treatment. The latter threshold was chosen a priori because it triggered phosphate supplementation in clinical practice during the study period (Table 1) . Dialysis dose was calculated from the total effluent discharged per day divided by the patient's baseline weight for the first 3 days, thus incorporating downtime due to interruptions into the 24-h dose delivered [16] .
Statistical analysis
Continuous variables were analyzed with Student's t-tests and categorical variables were compared using the chi-square test; nonparametric statistics were used when appropriate. We evaluated factors associated with baseline serum phosphate levels using multivariate linear regression and decline in serum phosphate during CVVHD using multivariate logistic regression. Time to prolonged ventilatory support requiring tracheostomy, and allcause 28-day mortality were examined via multivariable proportional hazards models; the former was performed in a competing risk model. Serum phosphate decline to <2 mg/dL and ongoing dialysis treatment at time of event were coded as time-dependent covariates, which assume a null value in the model if a patient's serum phosphate is !2 mg/dL at time t and unity otherwise. All baseline variables are collected at initiation of CVVHD, unless otherwise specified. Prespecified interactions and higher order terms were examined in our model-building process. A two-sided P-value of <0.05 was considered statistically significant. Values were expressed as means (AE SD) or median (interquartile range). All analyses were performed using the SAS statistical package (SAS Institute Inc., Cary, NC).
Results

Demographics
The mean age of the 321 patients was 59 AE 14 years; 65% were male. Their Acute Physiology and Chronic Health Evaluation II score on admission was 24 AE 9; majority of patients had the clinical diagnosis of acute tubular injury (56%), required vasopressor support (61%) and mechanical ventilation (88%) at time of CVVHD initiation.
Hypophosphatemia
IHP, defined as serum phosphate <2 mg/dL during CVVHD, occurred in 87 (27%) patients (Table 1) . Mean serum phosphate levels showed a steep decline within the first 72 h of CVVHD ( Figure 1 ). In univariate analysis, gender, weight, dialysis dose delivered and CVVHD duration as well as baseline serum sodium, potassium and blood urea nitrogen (BUN) were associated with IHP. However, in multivariable analysis, dialysis duration per day [odds ratio (OR), 1.19; 95% confidence interval (CI), 1.1-1.3], dose per 10 mL/h/kg (OR, 2.1; 95% CI, 1.2-3.7), ischemic acute tubular necrosis etiology for renal failure (OR, 2.8; 95% CI, 1.3-6.3) and baseline BUN per 10 mg/dL (OR, 0.88; 95% CI, 0.79-0.99) were independently associated with IHP. Serum phosphate or feeding route (none, enteral or parenteral) at dialysis initiation were not associated with IHP in multivariate analysis.
Serum phosphate concentration at initiation of dialysis was independently associated with age (b coefficient,
Respiratory failure
The majority of patients (88%) were ventilator dependent at initiation of dialysis, which did not correlate with baseline serum phosphate (5.4 AE 2.3 versus 5.6 AE 1.9, P ¼ 0.5) or IHP (Table 1) . Nineteen percent of patients were extubated and 23% had pre-longed respiratory failure requiring tracheostomy, with a median dialysis start to extubation/ tracheotomy time of 8 and 13, respectively. IHP was associated with higher rates of chronic respiratory failure requiring tracheostomy but similar dialysis start to tracheostomy time but did not correlate with successful extubation or dialysis start to extubation time ( Table 2 ). The absence of statistical difference in dialysis start to extubation time in the two groups is due to higher incidence of tracheostomy in the IHP group, which is a competing end point. The cumulative incidence curves in Figure 2 show the occurrence of tracheostomy per IHP in 28 days of follow-up.
In time-to-tracheostomy competing-risk multivariate proportional hazards analysis, IHP coded as a timedependent covariate predicted chronic respiratory failure requiring tracheostomy (hazard ratio [HR] ¼ 1.8; 95% CI ¼ 1.07-3.08), independent of baseline serum phosphate (HR ¼ 0.9; 95% CI ¼ 0.8-1.0) and parenteral nutrition (HR, 2.0; 95% CI ¼ 1.1-3.4) ( Table 3) .
Mortality
Twenty-eight-day all-cause mortality was 66%; IHP was not associated with higher mortality in univariate analysis ( Table 2 ). The multivariate proportional hazards analysis included previously reported mortality predictors and confirmed the lack of association between IHP and mortality (Table 3) .
Discussion
We have found that hypophosphatemia develops frequently during CVVHD in critically ill patients with AKI. The incidence increased with longer duration and higher intensity of renal replacement therapy. IHP was associated with higher incidence of prolonged respiratory failure requiring tracheostomy but not 28-day all-cause mortality.
Intensity and duration of CVVHD were strong predictors of IHP in the current study, independent of serum phosphate levels and feeding route at initiation of dialysis treatment. The higher incidence of hypophosphatemia with intensive therapy was a consistent finding in two recent large-scale clinical trials [20, 21] . In Acute Renal Failure Trial Network Study, hypophosphatemia occurred in 17.6% of patients in the intensive-therapy group as compared to 10.9% in the group undergoing less intensive therapy, and 65.1 versus 54% in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy study. Neither study, however, reported an increased incidence of serious adverse events in the intensive-therapy group. The high rate of severe hypophosphatemia (<2 mg/dL) observed in our cohort, despite standard dose intensity, is likely due to several factors: limiting our study cohort to CVVHD as initial mode of therapy [24] , daily measurements of serum phosphate levels during CVVHD which minimizes detection bias due to underreporting and the lack of preemptive parenteral or dialysate phosphate supplementation at the time of the study in our center [19] . While older age, female gender and nutrition markers such as low serum creatinine and parenteral feeding were associated with low serum phosphate levels at CVVHD initiation; the trend for association between baseline phosphate levels at CVVHD initiation and IHP observed in univariate analysis did not persist in the adjusted model.
Respiratory failure
In the present study, severe IHP (<2 mg/dL) was associated with a higher incidence of prolonged respiratory failure requiring tracheostomy. The latter association was examined in the context of not only respiratory outcome but also the more likely outcome of death competing with tracheostomy [25] . Indeed, many have previously implicated hypophosphatemia as a cause for respiratory failure through its impact on respiratory muscles [1] [2] [3] 26] . Fisher et al. [27] reported high incidence of respiratory complications among patients who had hypophosphatemia on admission; although hospital stay was twice as long in hypophosphatemic patients, their mortality was no different. On the other hand, acid-base derangements, common in patients with respiratory failure, may alter renal phosphate excretion; however, renal handling of phosphate is unlikely to play a major role in patients with AKI requiring support with renal replacement therapy [14, 26, 28, 29] . Arguably, this finding is confounded by attempts at phosphate repletion. However, even though serum phosphates appear to be within normal levels with correction, intracellular levels may be reduced or continuously depleted with ongoing CVVHD. Therefore, detection of IHP during CVVHD presages respiratory failure.
Mortality
There are no previous studies that have investigated the association of hypophosphatemia and mortality in patients with AKI maintained on CVVHD. Although kidney replacement therapies in general may save lives, the impact of inadvertent therapy-related factors as a cause of excess mortality has not been assessed systematically. In a surgical intensive care unit, Zazzo et al. observed an association between hypophosphatemia that developed in 28.8% of heterogenous cohort of patients and mortality. Shor et al. confirmed the association between hypophosphatemia and mortality in exclusively septic patients and suggested that inflammation may play an intermediary role [6, 13, [30] [31] [32] .
We observed a trend for positive association between high serum phosphate at initiation of CVVHD and mortality, which may be an indicator for severity of renal failure. However, IHP during CVVHD, driven mainly by intensive and prolonged therapy, was not associated with higher mortality ( Table 2) .
Management of hypophosphatemia during CVVHD
Phosphate can be added to replacement and/or dialysate solutions or administered separately in a replacement protocol to reduce the incidence of hypophosphatemia and the need for ad hoc intravenous treatment. Phosphate therapy, however, has not been proven to be safe in patients with AKI requiring renal replacement. Rapid fluctuations associated with intravenous administration may potentially contribute to hypocalcemia, nephrocalcinosis and metastatic calcification [33, 34] . Troyanov et al. have demonstrated, in a small cohort of patients requiring CVVHD, the safe and practical addition of potassium phosphate to calcium-containing dialysate solutions without any precipitation. Similarly, Santiago et al. [19] have added monosodium phosphate to the replacement and dialysate solutions in 38 pediatric patients without any complications reported. Moreover, calcium-phosphate precipitation is not a concern when regional citrate anticoagulation is used with calcium-free dialysate and replacement solutions. In our center, we usually use enteral sodium phosphate preparations when serum phosphate levels are between 0.5 and 2.0 mg/dL and intravenous sodium phosphate when <0.5 mg/dL. Although not standardized through protocols, practice was largely homogenous as CVVHD was supervised by the same attending physician for >90% for the duration of the study period.
Limitations
Although our study is limited by its observational design, it is a large homogenous prospective cohort of patients initiated on CVVHD with a standard bicarbonate-based dialysate solution [16] . Phosphate measurements were performed routinely while on CVVHD in our institution, subsequently unavailable data, though low in proportion, are assumed to be missing at random. We did not have standardized protocols for serum phosphate replacement and this may confound the analysis of hypophosphatemia. The large sample size and high event rate has allowed us to adjust for a large number of covariates in our analyses. Future research investigating long-term outcomes beyond the duration of this study is also needed.
Conclusions
Hypophosphatemia occurs frequently during CVVHD, particularly with longer and intensive treatment. Low serum phosphate levels during CVVHD were associated with higher incidence of prolonged respiratory failure requiring tracheostomy but not with 28-day all-cause mortality. We suggest further investigation regarding the means and the extent of safe phosphate replacement and its effect on respiratory weaning.
